Transitional Year·Trinity, FL

HCA Florida Healthcare/USF Morsani College of Medicine GME - Tampa North/Trinity Hospital

Signal lift23%35%+12 pp with a signal here
Allocate signal →Track an away here25-26 cycle · applicant-level
Step 2 invited
239–266
p10 – p90
Sample N
602
applicants this cycle
This cycle
-
no tracked aways yet
Match rate
1.5%
9 of 602 applicants
01Cohort funnelthis cycle
N = 602
Applied
602
100.0%
Invited
105
17.4%
Class size
9
1.5%
J-1 visaGraduated within 2 yearsPreliminaryHospitalist
Your fitHCA Florida Healthcare/USF Morsani College of Medicine GME - Tampa North/Trinity Hospital Program

Create a free profile to see your personalized fit

Get started
Applicant profile2025 data

What successful applicants at this program look like.

See how competitive you are here

Compare your stats against applicants at HCA Florida Healthcare

Create free account

Who to contact

Training sites2 hospitals
  • 1
    HCA Florida Trinity Hospital
    Trinity, FL
    Primary
  • 2
    HCA Florida Healthcare/USF Morsani College of Medicine GME
    Tampa, FL
    Sponsor
Interview invites
Loading...
Score rangesinvited cohort
USMLE Step 2 CK239 – 266
180205230255280
COMLEX Level 2 CE443 – 679
400500600700800
Interview rates
US MD
20%
US DO
26%
US IMG
10%
Non-US IMG
0%
Applicant origin
In-state
49%
Out-of-state
11%
Interview prepTransitional Year
personalTell me about yourself.★ common
specialtyWhy did you choose this specialty?★ common
programWhy are you interested in our program?★ common
behavioralWhat are your strengths and weaknesses?★ common
personalWhere do you see yourself in 5-10 years?★ common
Save this program

Add HCA Florida Healthcare/USF Morsani College of Medicine GME - Tampa North/Trinity Hospital to your list

Build a personal match list. Compare programs side-by-side, see how your timing stacks against peers, and get notified when peers hear back.

Next

Calculate your match probability for Transitional Year.

See how your profile compares across all programs.

Open calculator →

Program data, 2025 release. Not medical advice. © 2026 Rezumab LLC.